Bausch Health Companies (NYSE:BHC) had its price objective decreased by Morgan Stanley from $34.00 to $32.00 in a research report released on Tuesday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.
Several other equities research analysts have also weighed in on the company. Cowen started coverage on Bausch Health Companies in a research note on Friday, October 25th. They set an outperform rating and a $35.00 price objective for the company. JPMorgan Chase & Co. raised Bausch Health Companies from a neutral rating to an overweight rating and raised their price objective for the stock from $32.00 to $38.00 in a research note on Thursday, December 12th. TheStreet raised Bausch Health Companies from a d+ rating to a c rating in a research note on Thursday, December 12th. Wells Fargo & Co raised Bausch Health Companies from an underweight rating to an equal weight rating and set a $32.00 price objective for the company in a research note on Wednesday, January 22nd. Finally, Goldman Sachs Group started coverage on Bausch Health Companies in a research note on Monday, December 2nd. They set a neutral rating and a $30.00 price objective for the company. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $34.06.
BHC opened at $27.74 on Tuesday. The firm has a market cap of $9.67 billion, a PE ratio of 6.38, a P/E/G ratio of 0.57 and a beta of 1.02. The company has a quick ratio of 0.86, a current ratio of 1.15 and a debt-to-equity ratio of 9.17. The business has a fifty day simple moving average of $28.82 and a 200-day simple moving average of $25.51. Bausch Health Companies has a fifty-two week low of $18.72 and a fifty-two week high of $31.97.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Featured Article: Trading Strategy Methods for Individual Investors
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.